TY  - JOUR
N1  - The Copyright of this article belongs to Informa healthcare
ID  - open2951
UR  - https://www.tandfonline.com/doi/abs/10.1080/08830185.2021.1990277?journalCode=iiri20
A1  - Kalra, Rashi
A1  - Tiwari, Drishti
A1  - Dkhar, H Kitdorlang
A1  - Bhagyaraj, Ella
A1  - Kumar, Rakesh
A1  - Bhardwaj, Anshu
A1  - Gupta, Pawan
Y1  - 2021/09/22/
N2  - Despite new approaches in the diagnosis and treatment of tuberculosis (TB), it continues to be a major health burden. Several immunotherapies that potentiate the immune response have come up as adjuncts to drug therapies against drug resistant TB strains; however, there needs to be an urgent appraisal of host specific drug targets for improving their clinical management and to curtail disease progression. Presently, various host directed therapies (HDTs) exist (repurposed drugs, nutraceuticals, monoclonal antibodies and immunomodulatory agents), but these mostly address molecules that combat disease progression.
PB  - Informa healthcare
JF  - International reviews of immunology
KW  - Host directed therapy (HDT); host epigenetic machinery; host transcription factors (TFs); host-pathogen interaction; tuberculosis (TB)
SN  - 1563-5244
TI  - Host factors subverted by Mycobacterium tuberculosis: Potential targets for host directed therapy
ER  -